Business
Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT
- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention - - As in other studies, etripamil was well tolerated
About this update from Milestone Pharmaceuticals Inc.
[{"type":"text","content":"- Patients successfully self-managed PSVT episodes with etripamil which reduced need for ED intervention -\n- As in other studies, etripamil was well tolerated by patients -\n- Data to be featured during late breaking session at Heart Rhythm 2022 -\nMONTREAL and CHARLOTTE, N.C., April 30, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced data from NODE-302, its Phase 3 open-label extension study of etripamil nasal spray, the Company's novel, investigational, calcium channel blocker in patients with paroxysmal supraventricular tachycardia (PSVT). The presentation, titled \"Etripamil Nasal Spray Is Effective and Safe for Conversion of Repeated Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia During Long-term Follow-up: Results From the NODE-302 Study,\" will be featured during a late-breaking clinical trial session at the Heart Rhythm Society's Heart Rhythm 2022 meeting being held April 29-May 1, 2022 in San Francisco.\n\"PSVT is a highly disruptive condition that places a heavy burden on patients because of the unpredictable and sudden onset of symptoms that can require visits to the emergency department (ED) for treatment,\" said James Ip, M.D., Associate Professor and Director of Cardiac Pacing and Implantable Devices, Division of Cardiology, Weill Cornell Medicine, New York Presbyterian Hospital, and the study's lead author. \"Results from the NODE-302 trial support the potential role of etripamil intranasal spray for patients to safely and effectively self-treat recurrent PSVT episodes without direct medical supervision and reduce their need for ED visits.\"\n\"These data, which show that 85% of the eligible patients chose to enter the NODE-302 extension study after experiencing etripamil administration in the prior study, are very encouraging as we progress in our mission of helping patients suffering from tachycardias,\" said Joseph Oliveto, President and Chief Executive Officer of Milestone Pharmaceuticals. \"I would like to thank Dr. Ip and all the NODE-302 study investigators, study personnel, and our Milestone team members for generating these data, and the patients for putting their trust in our program.\"\nNODE-302 was a single-arm, open-label extension s...